论文信息 - Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions - 字舞流文

Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions

John P. Overington | Suleiman A. Khan | A. Leach | T. Aittokallio | A. Hersey | K. Wennerberg | B. Seashore-Ludlow | Abhishekh Gupta | M. Vähä-Koskela | L. Yetukuri | A. Jaiswal | Jing Tang | Liye He | E. Karjalainen | Ziaurrehman Tanoli | B. Ravikumar | Zaid Alam | A. Rebane | Gopal Peddinti | A. V. van Adrichem | Janica Wakkinen | Prson Gautam | Elina Parri | Mehreen Ali | A. Gustavsson | G. Repasky | Alok Jaiswal | Balaguru Ravikumar | Anni Rebane

[1] A. Plowright,et al. Joining Forces: The Chemical Biology-Medicinal Chemistry Continuum. , 2017, Cell chemical biology.

[2] Gerhard Dürnberger,et al. A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor. , 2017, Nature chemical biology.

[3] Balaguru Ravikumar,et al. C-SPADE: a web-tool for interactive analysis and visualization of drug screening experiments through compound-specific bioactivity dendrograms , 2017, Nucleic Acids Res..

[4] Jacob K. Asiedu,et al. The Drug Repurposing Hub: a next-generation drug library and information resource , 2017, Nature Medicine.

[5] Steven J. M. Jones,et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer , 2017, Nature Genetics.

[6] Tudor I. Oprea,et al. A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.

[7] Yanli Wang,et al. PubChem BioAssay: 2017 update , 2016, Nucleic Acids Res..

[8] George Papadatos,et al. The ChEMBL database in 2017 , 2016, Nucleic Acids Res..

[9] Florian Nigsch,et al. Evidence-Based and Quantitative Prioritization of Tool Compounds in Phenotypic Drug Discovery. , 2016, Cell chemical biology.

[10] S. Chakradhar. Group mentality: Determining if targeted treatments really work for cancer , 2016, Nature Medicine.

[11] John P. Overington,et al. The promise and peril of chemical probes. , 2015, Nature chemical biology.

[12] John P. Overington,et al. Chemical databases: curation or integration by user-defined equivalence? , 2015, Drug discovery today. Technologies.

[13] Tudor I. Oprea,et al. Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes , 2015, Cell.

[14] Krister Wennerberg,et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation , 2015, Nature.

[15] S. Friend,et al. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. , 2015, Cancer discovery.

[16] Joshua A. Bittker,et al. Evolving BioAssay Ontology (BAO): modularization, integration and applications , 2014, J. Biomed. Semant..

[17] J. Crispino,et al. The Aurora Kinases in Cell Cycle and Leukemia , 2014, Oncogene.

[18] Tao Xu,et al. Making Sense of Large-Scale Kinase Inhibitor Bioactivity Data Sets: A Comparative and Integrative Analysis , 2014, J. Chem. Inf. Model..

[19] John P. Overington,et al. Global Analysis of Small Molecule Binding to Related Protein Targets , 2012, PLoS Comput. Biol..

[20] Mindy I. Davis,et al. Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[21] Peter Murray-Rust,et al. Minimum information about a bioactive entity (MIABE) , 2011, Nature Reviews Drug Discovery.

[22] Sungjoon Kim,et al. Ba/F3 cells and their use in kinase drug discovery , 2007, Current opinion in oncology.

[23] E. Burton,et al. Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human , 1999, Biopharmaceutics & drug disposition.

[24] Julian Blagg,et al. A public-private partnership to unlock the untargeted kinome. , 2013, Nature chemical biology.